Navigation Links
SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
Date:8/6/2008

BELLEVUE, Wash., Aug. 6 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) announced today that it has submitted to the Food and Drug Administration an Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on the Company's patented Controlled Delivery Technology (CDT(R)) platform. This is the first application submitted by SCOLR based on its CDT platform.

Pseudoephedrine is an active ingredient in Allegra(R) D, Sudafed(R) PSE, Claritin(R) D, Zyrtec(R) D and other over-the-counter (OTC) and prescription products as a decongestant. The domestic OTC decongestant market for pseudoephedrine-containing products is estimated to exceed $1 billion annually.

Stephen J. Turner, SCOLR's Vice President and Chief Technical Officer, stated, "We believe the primary advantages our formulation may have over currently marketed pseudoephedrine tablets relates to the overall efficiency of the formulation. We were able to demonstrate bio-equivalence for our product while significantly reducing the overall tablet size, gaining important manufacturing margin advantages over currently available tablets.

"Since pseudoephedrine tablets now face marketing pressure because of required placement behind the counter in the pharmacy, we believe that margin and size may play an important role in the selection process for consumers, and could give SCOLR an advantage in the competitive store-brands and private label marketplace."

"The ANDA for pseudoephedrine is a major accomplishment for SCOLR," said Daniel O. Wilds, the Company's Chief Executive Officer. "Approval of this product would further substantiate some of the unique advantages of our drug delivery technology and can be an important revenu
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
2. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
3. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
4. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
5. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
6. TriServ Alliance Submits Bid for TRICARE South Region Contract
7. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
8. Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
10. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
11. Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 As the Mayo Clinic's 2012 ... Ford & Associates Nationwide Legal Services, A.P.C., comments on ... lawsuit: Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, ... , “In light of a recently filed lawsuit, Ford ... evaluate and explore the Mayo Clinic's Benicar case study ...
(Date:3/5/2015)... London, UK (PRWEB) March 06, 2015 ... of them being first–in-class. AstraZeneca tops the list scoring ... field obtained over 25% of all FDA approved drug ... total. First-in-class mechanisms such as anti-PCSK9, anti-PD1 and CDK ... have been approved by the FDA to treat metastatic ...
(Date:3/5/2015)... 2015 This week, 60 ... low-cost laminate flooring products, initiating widespread concern from ... building materials made primarily from bamboo, stands behind ... their flooring products for volatile organic compounds (VOCs) ... International (BMH). Results from formaldehyde emissions testing ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Risperdal ... in a Pennsylvania mass tort litigation currently underway ... a jury has begun hearing testimony in the ... atypical antipsychotic medication can cause gynecomastia, or male ... in question was filed on behalf of a ...
(Date:3/5/2015)... 2015 Rhode Island Medical Imaging (RIMI) was ... row to support the Providence College (PC) women’s basketball program’s ... purchase of the ‘Think Pink’ uniforms, which were worn during ... opponent DePaul University at Alumni Hall/Mullaney Gymnasium in Providence, R.I. ... of the PC women’s basketball’s ‘Pink Out’ event,” said Dr. ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2
... have been hit hard with the government banning the ... foot-and-mouth disease in the kingdom.// ,A Bhutan government ... affects all species of cloven-hoofed animals were being reported ... district, bordering India's northeastern state of Assam. ,"The ...
... tumor which is found resistant to most of the ... The main causative agents for the development of Malignant ... virus 40 (SV40) is also found to be a ... people with malignant mesothelioma have worked or lived in ...
... born at night have an increased risk of death, by ... times of the day said a new research published in ... ,Researchers for Division of Neonatal and Developmental Medicine, Stanford University, ... more for babies in their first month of life than ...
... Saturday administered a "defeat AIDS pledge"// to people in ... ,India has 5.13 million people infected with HIV/AIDS. Andhra ... the country with more than 400,000 affected people. According ... prevalence rate is an alarmingly 2.25 percent among antenatal ...
... affecting the left-brain than the right brain, said a ... ,The authors state that discrepancy could be due to ... ,Cerebrovascular events are frequently accompanied by characteristic neurological deficits, ... occurs. People with events on the left side of ...
... marketed as functional food ingredients, or even synthesized for use ... able to identify the molecular structure of flavonols found in ... They also say that they are able to synthesize not ... specific needs. , ,Several studies in recent years have ...
Cached Medicine News:Health News:Malignant Mesothelioma – A New Genetic Revelatio 2Health News:Malignant Mesothelioma – A New Genetic Revelatio 3Health News:"Defeat AIDS Pledge" by Andhra CM 2Health News:Stroke In The Right-Brain Can Remain Undiagnosed 2
(Date:3/5/2015)... , March 5, 2015  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, today announced ... to advisory roles. The panel of experts will ... and efforts to advance the company pipeline of ... bring expertise in a range of areas including ...
(Date:3/5/2015)...  Celsion Corporation (NASDAQ: CLSN ) ... conference call to discuss year-end 2014 financial results ... for ThermoDox®, its proprietary heat-activated liposomal encapsulation of ... and TheraSilence™, in immunotherapy and RNA delivery at ... To participate in the call, interested parties may ...
(Date:3/5/2015)... -- LUNGevity Foundation, the nation,s leading lung cancer ... approval of Bristol Myers Squibb,s new immunotherapy drug ... another critical new treatment option to fight lung ... own immune system to fight cancerous cells. Importantly, ... with squamous cell lung cancer, a population for ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3
... DURHAM, N.C., Sept. 16, 2011 Chimerix, Inc., ... today that investigators will present preliminary data for ... Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ... Genovefa Papanicolaou, M.D., Associate Member of Infectious Diseases ...
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced the introduction of ... States. The black and white portable unit provides outstanding ... for use in numerous specialty markets. With DP-50,s launch, ...
Cached Medicine Technology:Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting 2Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting 3Mindray Introduces DP-50 Portable Ultrasound System in the U.S. 2Mindray Introduces DP-50 Portable Ultrasound System in the U.S. 3
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... For the qualitative differential ... (P.f) antigen and an antigen ... four species of malaria:plasmodium falciparum ... ovale (P.o) and Plasmodium malariae ...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
Medicine Products: